Fig. 7: LCAs as a powerful preclinical model for personalized drug testing.
From: A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments
a Heterogeneous responses of LCAs and LCOs derived from 6 patients with lung adenocarcinomas to the carboplatin-based chemotherapies. The fitted dose–response curves illustrate the responses of the LCAs and LCOs to pemetrexed + carboplatin (PC) (n = 3 biologically independent samples). b The heat map is LogIC50 values of exemplary LCAs and LCOs in Fig. 7a and Supplementary Fig. 9a. TC, taxol + carboplatin. R means the IC50 is not available, and the samples are resistant to the drugs. c The distribution of CVs in the drug-sample pairs in the LCA and LCO groups. (n = 42 drug-sample pairs). d Dose response curves of various LCAs of nine different patients to Furmonertinib (n = 3 biologically independent samples). The right were the comparisons of both the area under the dose–response curve (AUC-DRC) and the viability at the indicated concentration (0.1 μM) between EGFR mutation (EGFR-M, n = 3 patients, LC19, LC46 and LC69) and the EGFR wild-type (EGFR-W, n = 6 patients) groups. e Flowchart of procedures and treatments for LC46 patient with EGFR mutation. f Dose response curves of different drugs on LCA 46. g CT scan images of patient LC46 before and after neoadjuvant therapy. The size of the lung tumor, indicated by red arrow, decreased from 8.6 × 5.1 cm2 to 3.5 × 3.4 cm2 after neoadjuvant therapy (Taxol + Carboplatin + Furmonertinib). h The drug-response profile of LCAs from patient LC42. NC, negative control. Cis, Cisplatin. Pem, Pemetrexed (n = 3 biologically independent samples). i CT images of patient LC42 before and after neoadjuvant therapy. The size of the lung tumor, indicated by red arrow, decreased from 4.5 × 4.4 cm2 to 2.0 × 1.1 cm2 after 2 cycles of neoadjuvant therapy (Taxol + Carboplatin + PD-1). j The heat map of in vitro drug responses based on LCA test and clinical outcomes of 7 patients based on RECIST. CR, Complete response. PR, Partial response, SD, Stable disease. Scale bar, yellow bar, 200 μm; two-sided Student’s t test is used and data are presented as mean ± S.E.M. Source data are provided as a Source Data file.
